Stockreport

Innosphere starts paediatric clinical trial for Novostim ADHD device [Yahoo! Finance]

Akili, Inc.  (AKLI) 
PDF The randomised, sham-controlled trial will evaluate the Novostim 2 device in children with ADHD aged 7-12 years. The data from the study will be used to seek clearance [Read more]